bye bye

Quote






there will be your just not good enough or trusted enough to sell it face it if you were you’d go work in oncology today and we both know that ain’t happening for u. So they may suck but guess what so do u
 






DSI is posting many oncology jobs, why would Japan authorize these if oncology will be partnered off? How is the zelboraf co-promote with Genentech- anyone from DSI supporting it?
 






anonymous said:
DSI is posting many oncology jobs, why would Japan authorize these if oncology will be partnered off? How is the zelboraf co-promote with Genentech- anyone from DSI supporting it?
Click to expand...

no one is working on zelboraf since 2017 and for AML they are hiring like 25 people maybe a few sneak through but not many and that’s a tiny product for future products they’re close to naming a partner that will sell it
 


















AML drug showed significant survival improvement, so it can't be that bad. Novartis' Rydapt is on track to make $150 mil this year, if managed well DSI could get a chunk of this. not a blockbuster but keeps some lights on.
 






better read more closely, rydapt is first line and quiz is for r/r and will be behind another competitor so a tiny number of patients and 6 weeks is not a great result for a drug that may cost 25k a year, it would be like a doctor using eluquis, patient fails then Xarelto patient fails then savaysa you ever see that happen? Of course not go get educated just look up number if r/r patients with FLT
 






anonymous said:
AML drug showed significant survival improvement, so it can't be that bad. Novartis' Rydapt is on track to make $150 mil this year, if managed well DSI could get a chunk of this. not a blockbuster but keeps some lights on.
Click to expand...

Astellas dukes the same product in April so they are a year ahead of us. They have simple dosing we have 5 doses and regular ECGs, they’ve done tons of studies in US we’ve done none. Being honest don’t expect much here, internally we do not. Visit clinical trials and compare what they do versus us, Tom
 






one more example of development failing again and CE, there will be no patients left to treat and go look up the study design for the products ours is a complete cluster just one more piece of proof that most here don’t know oncology at all. thanks Anton and Glen another winner
 






One more example of being a slow follower, multiple ONC failures and now one that will be late to market, very few patients and have all kinds of disadvantages, it will fail and the will blame the sales team as always
 


















you realize this is because both the top sales people and sales managers have left or have been let go. You cannot sell with what you have. And it is true, no support from Corporate or your managed care team. This is a simple equation
 






anonymous said:
you realize this is because both the top sales people and sales managers have left or have been let go. You cannot sell with what you have. And it is true, no support from Corporate or your managed care team. This is a simple equation
Click to expand...

U realize that the top people here are the bottom of the barrel anywhere else right? If they wer so good how come they can’t find work? Or if they do find work it’s with a lousy company? Or the former great managers why aren’t they hiring you or others? Company’s get talent because of who they are or the products they sell and that isn’t DSI and it’s Japan that could care less and throw finance in there too
 












Top Bottom
Back
Quote